Group One Trading
CCCC icon

Group One Trading’s C4 Therapeutics CCCC Stock Holding History

Group One Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21K Buy
6,300
+1,400
+29% +$5.22K ﹤0.01% 5838
2026
Q2 		$22.9K Buy
4,900
+4,800
+4,800% +$16.4K ﹤0.01% 5927
2026
Q1 		$263 Sell
100
-3,000
-97% -$7.06K ﹤0.01% 7379
2025
Q4 		$5.92K Sell
3,100
-54,000
-95% -$128K ﹤0.01% 7105
2025
Q3 		$127K Buy
57,100
+47,100
+471% +$113K ﹤0.01% 5125
2025
Q2 		$14.3K Buy
10,000
+9,900
+9,900% +$14.4K ﹤0.01% 6493
2025
Q1 		$160 Sell
100
-600
-86% -$1.79K ﹤0.01% 7385
2024
Q4 		$2.52K Sell
700
-54,500
-99% -$271K ﹤0.01% 6665
2024
Q3 		$315K Buy
55,200
+30,900
+127% +$186K ﹤0.01% 3223
2024
Q2 		$112K Sell
24,300
-34,100
-58% -$203K ﹤0.01% 3875
2024
Q1 		$477K Sell
58,400
-120,800
-67% -$936K ﹤0.01% 2784
2023
Q4 		$1.01M Buy
+179,200
New +$409K ﹤0.01% 2454
2023
Q3 		– Sell
-100
Closed -$275 – 7680
2023
Q2 		$275 Buy
+100
New +$321 ﹤0.01% 7439

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Group One Trading's CCCC Position: Q3 2026 in Review

Group One Trading increased its C4 Therapeutics (CCCC) stake by 13% in Q3 2026, buying an estimated $10.6K and bringing the position to 24,612 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #4869.

Group One Trading first reported a position in CCCC in Q3 2021 and has held it in 10 quarters since. The position peaked at $118K in Q4 2024. 91 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Group One Trading held 24,612 shares of C4 Therapeutics worth $82K as of Q3 2026.
  • Group One Trading bought 2,839 C4 Therapeutics shares in Q3 2026, an estimated $10.6K.
  • C4 Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #4869 holding.
  • Group One Trading first reported a position in C4 Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • Group One Trading's C4 Therapeutics position peaked at $118K in Q4 2024.
  • 91 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.